N-acetyl cysteine treatment preserves mitochondrial indices of functionality in the brain of hyperammonemic mice

Hamidreza Mohammadi1,2, Abolfazl Sayad2, Mohsen Mohammadi3, Hossein Niknahad1,2, Reza Heidari1

1Pharmaceutical Sciences Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
2Department of Pharmacology and Toxicology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran
3Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran

Abstract

Aim of the study: Acute or chronic liver failure could result in hyperammonemia and hepatic encephalopathy (HE). HE is a clinical complication characterized by severe cognitive dysfunction and coma. The ammonium ion (NH4+) is the most suspected toxic molecule involved in the pathogenesis of HE. NH4+ is a neurotoxic agent. Different mechanisms, including oxidative/nitrosative stress, inflammatory response, excitotoxicity, and mitochondrial impairment, are proposed for NH4+ -induced neurotoxicity. N-acetyl cysteine (NAC) is a well-known thiol-reductant and antioxidant agent. Several investigations also mentioned the positive effects of NAC on mitochondrial function. In the current study, the effect of NAC treatment on brain mitochondrial indices and energy status was investigated in an animal model of HE.

Material and methods: Acetaminophen (APAP)-induced acute liver failure was induced by a single dose of the drug (800 mg/kg, i.p.) to C57BL/6J mice. Plasma and brain levels of NH4+ were measured. Then, brain mitochondria were isolated, and several indices, including mitochondrial depolarization, ATP level, lipid peroxidation, glutathione content, mitochondrial permeabilization, and dehydrogenase activity, were assessed.

Results: A significant increase in plasma and brain NH4+ was evident in APAP-treated animals. Moreover, mitochondrial indices of functionality were impaired, and mitochondrial oxidative stress biomarkers were significantly increased in APAP-treated mice. It was found that NAC treatment (100, 200, and 400 mg/kg, i.p.) significantly mitigated mitochondrial impairment in the brain of APAP-treated animals.

Conclusions: These data suggest the effects of NAC on brain mitochondrial function and energy status as a pivotal mechanism involved in its neuroprotective properties during HE.

Key words: bioenergetics, hepatic encephalopathy, mitochondria, neurotoxin, oxidative stress.

Introduction

Hepatic encephalopathy (HE) is a clinical complication defined as an elevated serum and brain level of ammonia because of liver failure. Acute and chronic liver injury induced by diseases or xenobiotics is associated with hepatic failure, impairment of ammonia detoxification, and HE [1]. HE and hyperammonemia could lead to brain injury, cognitive dysfunction, coma, or even patients' death [1].

Ammonia is the most suspected neurotoxic molecule involved in the pathogenesis of HE [2, 3]. Several mechanisms have been proposed for ammonia neurotoxicity [3-6]. Oxidative/nitrosative stress, inflammatory response, excitotoxicity, and disturbances in cellular calcium homeostasis are proposed to be involved in...
ammonia neurotoxicity [3-6]. Mitochondrial impairment and brain energy crisis represent another interesting mechanism for ammonia-induced brain injury [3, 7-11]. It has been found that ammonia is accumulated in mitochondria through specific transporters [9, 12]. Hence, this toxic molecule reaches a high level in the mitochondrial matrix [9, 12]. It has been found that NH4+ could inhibit vital enzymes involved in energy metabolism [3, 13-16]. Moreover, the effects of NH4+ on the mitochondrial electron transport process, mitochondrial membrane potential, and mitochondrial permeabilization have been well documented [3, 9, 12]. These events could lead to the collapse of mitochondrial adenosine triphosphate (ATP) production and a brain energy crisis. Moreover, NH4+-induced mitochondrial permeabilization could lead to the release of cell death mediators from this organelle [3]. NH4+-induced brain mitochondrial impairment and energy crisis could be connected to cognitive dysfunction or permanent brain injury during HE [3]. All these events highlight the pivotal role of mitochondrial impairment in the pathogenesis of HE.

N-acetyl cysteine (NAC) is used as a drug of choice against acetaminophen hepatotoxicity [17]. On the other hand, several pharmacological properties have been identified for NAC [18]. NAC has been widely investigated for different forms of xenobiotic-induced toxicity [19-22]. The positive effects of NAC supplementation against different diseases also have been documented [18, 23, 24]. The effects of NAC on oxidative stress and its associated events is the most plausible mechanism for its protective properties in biological systems [24, 25]. NAC could directly interact with reactive species [24, 25]. Moreover, NAC is able to significantly enhance cellular enzymatic antioxidant defense systems [24, 25]. NAC administration preserves cellular glutathione (GSH) at a high level [24, 25]. GSH and its associated enzymatic systems are the most pivotal cellular antioxidant mechanisms [24, 25]. Interestingly, the positive effects of NAC on mitochondrial function also have been mentioned in previous studies [26-29]. It has been found that NAC could significantly enhance cellular ATP levels and prevent mitochondria-mediated cell death and organ injury [26-29].

The effects of NAC on several neurological disorders have been investigated [23, 30]. On the other hand, previously, we found that NAC administration could significantly suppress brain oxidative stress biomarkers and improve locomotor activity in APAP-treated animals [31]. The current study was designed to evaluate the effects of NAC on brain mitochondria and energy level as pivotal mechanisms involved in ammonia neurotoxicity.

Material and methods

Chemicals

4,2-Hydroxyethyl,1-piperazine ethane sulfonic acid (HEPES), 6-hydroxy-2,5,7,8-tetramethyl chroman-2-carboxylic acid (Trolox), phenol, thiobarbituric acid (TBA), reduced GSH, rhodamine 123, 2’7’-di-chlorofluorescein diacetate (DCFH-DA), malondialdehyde (MDA), potassium chloride (KCl), sodium phosphate dibasic (Na2HPO4), ethylenediaminetetraacetic acid (EDTA), oxidized glutathione (GSSG), Coomassie brilliant blue, methanol HPLC grade, ethylene glycol-bis (2-aminoethyl ether)-N,N,N’,N’-tetraacetic acid (EGTA), mannitol, acetonitrile HPLC grade, sucrose, and NAC were purchased from Sigma Chemical Co. (St. Louis, MO, USA). Acetyl-para-aminophenol (APAP; acetaminophen), trichloroacetic acid (TCA), calcium chloride, hydroxymethyl aminomethane hydrochloride (Tris-HCl), and ammonium chloride were purchased from Merck (Darmstadt, Germany). All salts for preparing buffer solutions were of analytical grade and prepared from Merck (Darmstadt, Germany).

Animals

Male C57BL/6J mice (n = 40; 20-25 g weight) were obtained from the Animal Breeding Center, Shiraz University of Medical Sciences, Shiraz, Iran. Animals were housed in a standard environment (ambient temperature of 23 ±1°C, a 12 L : 12 D photoschedule, along with ≈40% relative humidity). Mice had free access to a normal rodents’ diet (RoyanFeed, Laboratory animals’ food company, Esfahan, Iran) and tap water. Animal handling and use were approved by the ethics committee of Shiraz University of Medical Sciences (#14822).

Animal model of fulminant hepatic failure

Acetaminophen (APAP)-induced acute liver failure was induced by a single dose of the drug (800 mg/kg, i.p.) [32]. The treatments were as follows: 1) Control (vehicle-treated); 2) APAP (800 mg/kg dissolved in warm normal saline, 25 ml/kg); 3) APAP + NAC 100 mg/kg, i.p.; 4) APAP + NAC 200 mg/kg, i.p.; 5) APAP + NAC 400 mg/kg, i.p. NAC was administered intraperitoneally two hours after APAP. The doses for NAC, the time of treatment, as well as the APAP-induced HE model, were selected based on previous studies in this field [31, 32].
**Plasma and brain ammonia**

Plasma and brain ammonia levels were measured with standard kits based on the absorbance photometry method of phenate-hypochlorate reaction [33]. For assessing the NH$_4^+$ level in the brain tissue, first tissue extract was prepared. For this purpose, samples (100 mg) of the forebrain (cerebral cortex) were dissected, homogenized, and deproteinized in 3 ml of ice-cooled lysis solution (trichloroacetic acid, 6%, w/v, 4°C). After centrifugation (12,000 g, 10 minutes, 4°C), the supernatant was collected and neutralized with potassium carbonate (KHCO$_3$; 2 mol/l, pH = 7). Afterward, brain ammonia content was measured using standard kits [33].

**Brain mitochondria isolation**

Mice brain mitochondria were isolated based on the differential centrifugation method [34]. Animals' brain was excised, washed, and minced in the ice-cooled mitochondria isolation buffer (75 mM mannitol, 225 mM sucrose, 0.5 mM EGTA, 2 mM HEPES, 0.1% essentially fatty acid-free bovine serum albumin, and pH = 7.4) [34-36]. Then, tissue was homogenized in the mitochondria isolation buffer (1 : 10 v : w; buffer : tissue ratio) [34, 35, 37]. The brain tissue homogenate was centrifuged (1000 g, 20 min at 4°C) to remove intact cells and nuclei. Then, the supernatant was collected and further centrifuged at 10,000 g (4°C for 20 min) to precipitate the heavy membrane fractions (mitochondria). This step was repeated at least three times using the fresh mitochondria isolation buffer medium. Finally, the mitochondria pellet was suspended in 5 ml of incubation buffer (220 mM sucrose, 2 mM HEPES, 70 mM mannitol, and pH = 7.4) [34, 35, 37].

**Mitochondrial swelling and permeabilization**

Mitochondrial permeabilization was monitored by the light scattering method, as previously described [35]. Briefly, 100 µl of isolated brain mitochondria preparations (0.5 mg protein/ml) were suspended in the pre-warmed (30°C) swelling buffer (125 mM sucrose, 65 mM KCl, 10 mM HEPES, pH = 7.2) [38]. The light absorbance was monitored (λ = 540 nm) during 30 minutes of incubation (30 s intervals; constant temperature of 30°C) [35, 39]. Decreased light absorbance is consistent with an increase in mitochondrial volume [35]. The differences between the absorbance of each sample were measured and reported as maximal mitochondrial swelling amplitude [35].

**Mitochondrial ATP level**

Based on a previously reported procedure, mitochondrial ATP level was assessed by HPLC [40]. Briefly, 1 ml of isolated mitochondria (10 mg protein/ml) was mixed with 100 µl of ice-cooled TCA (50% w : v, 4°C), incubated on ice (10 min, 4°C), and centrifuged (15,000 g, 10 min, 4°C). Afterward, the supernatant was treated with 100 µl of ice-cooled 1 M KOH solution [40]. Then, samples were centrifuged (15,000 g, 10 min, 4°C), and 25 µl of the supernatant was injected into an HPLC system consisting of an LC-18 column (µBondapak, 4.6 × 250 mm). The mobile phase was composed of KH$_2$PO$_4$ (100 mM, pH = 7 adjusted with KOH), tetrabutylammonium hydroxide (1 mM), and acetonitrile (2.5% v : v). The flow rate of the mobile phase was 1 ml/min, and the UV detector was set at λ = 254 nm [40].

**Mitochondrial dehydrogenases activity**

Mitochondrial dehydrogenase activity was determined by the methyl tetrazolium (MTT) assay [41-43]. Briefly, a mitochondrial suspension (1 mg protein/ml) in a buffer containing 320 mM sucrose, 1 mM EDTA, and 10 mM Tris-HCl, pH = 7.4, was incubated with 40 µl of MTT (0.4% w : v) at 37°C (30 min, in the dark). Samples were centrifuged (10,000 g, 15 min), and the product of purple formazan crystals was dissolved in DMSO (1 ml) and centrifuged (15,000 g, 5 min). Then, samples absorbance at λ = 570 nm was measured with an EPOCH plate reader (BioTek Instruments, Highland Park, USA).

**Mitochondrial depolarization**

The mitochondrial ability to take up the cationic fluorescent dye, rhodamine 123, was used as an index of mitochondrial depolarization [35, 44, 45]. For this purpose, the mitochondrial fractions (0.5 mg protein/ml) were incubated with 10 µl of rhodamine 123 (final concentration 10 µM) in the depolarization assay buffer containing 125 mM sucrose, 65 mM KCl, 10 mM HEPES, pH = 7.2 (20 min, 37°C). Samples were centrifuged (10,000 g, 5 min, 4°C) and the fluorescence intensity of the supernatant was measured using a FLUOstar Omega (BMG Labtech, Germany) multifunctional microplate reader at the excitation and emission wavelengths of λ = 485 nm and λ = 525 nm, respectively [35, 46].

**Lipid peroxidation in brain mitochondria**

Mitochondrial formation of thiobarbituric acid reactive substances (TBARS) was measured as an index
of lipid peroxidation in this organelle [35, 47]. First, isolated brain mitochondria were washed to remove sucrose. For this purpose, mitochondria samples were added to 5 ml of an ice-cold MOPS-KCl buffer (50 mM MOPS, 100 mM KCl, pH = 7.4) and centrifuged (10,000 g, 20 min, 4°C). The pellet was re-suspended in fresh MOPS-KCl buffer. Afterward, the mitochondrial suspension (1 mg protein/ml) was mixed with twice its volume of TBARS assay reagent (trichloroacetic acid 15% w : v, thiobarbituric acid 0.375% w : v, HCl 2 N, and Trolox 0.5 mM). Then, the mixture was heated in a water bath (15 min at 100°C) [35, 48]. After centrifugation (10,000 g, 20 min), the absorbance of the supernatant was assessed at λ = 532 nm using an EPOCH plate reader (BioTek Instruments, Highland Park, USA) [35, 42].

**Mitochondrial glutathione content**

The levels of reduced (GSH) and oxidized (GSSG) glutathione in isolated brain mitochondria were measured by an HPLC method [49]. The HPLC system consisted of an NH2 column (Bischoff chromatography, Leonberg, Germany, 25 cm) and a UV detector (set up at λ = 254 nm) [49]. Buffer A (water : acetate buffer; 4 : 1 v : v) and buffer B (methanol : buffer A; 4 : 1 v : v) were used as mobile phases. A gradient method with a steady increase of buffer B to 95% was applied (in 25 min). The flow rate of the mobile phases was 1 ml/min [49]. Briefly, mitochondria samples (1 ml; 1 mg protein/ml) were treated with 50 µl of metaphosphoric acid (50% w : v). Samples were mixed well, incubated on ice (15 min, 4°C), and centrifuged (15,000 g, 15 min, 4°C). Afterward, 300 µl of NaOH : NaHCO₃ solution (2 M : 2 M) was added to the supernatant until the gas production was subsided. Then, 100 µl of iodoacetic acid (1.5% w : v in double-distilled water) was added, and samples were incubated for one hour in the dark (4°C). Then, 2,4-dinitrofluorobenzene (DNFB; 500 µl of 1.5% w : v in absolute ethanol) was added, samples were mixed well and incubated in the dark (25°C, 24 hours). Finally, samples were centrifuged (16,000 g, 25 min) and 25 µl of the supernatant was injected into the described HPLC system [49, 50].

**Statistical analysis**

Data are given as mean ± SD. The comparison of data sets was performed by one-way analysis of variance (ANOVA) with Tukey’s multiple comparisons as the post hoc test. A value of p < 0.05 was considered to indicate a statistically significant difference.

**Results**

Significant elevation in plasma and brain levels of ammonium ion (NH₄⁺) was evident in the APAP-treated animals (800 mg/kg, i.p.). On the other hand, it was found that NAC administration (100, 200, and 400 mg/kg, i.p.) significantly decreased plasma and brain ammonia levels (Fig. 1). Although the effect of NAC on plasma and brain ammonia levels was not dose-de-
in the current study (Fig. 1), the maximum effects of this compound on blood and brain ammonia was detected at the dose of 400 mg/kg (Fig. 1).

Mitochondrial indices of functionality, including mitochondrial dehydrogenase activity, ATP content, and mitochondrial membrane potential, were significantly decreased in the brain of APAP-treated (800 mg/kg, i.p.) mice (Fig. 2). Moreover, significant mitochondrial permeabilization was found in the APAP-treated group (Fig. 2). It was found that NAC treatment (100, 200, and 400 mg/kg, i.p.) improved mitochondrial function in hyperammonemic animals (Fig. 2). The effects of NAC on brain mitochondrial function were not dose-dependent (Fig. 2). However, the maximum effects of NAC on mitochondrial function were observed at the dose of 400 mg/kg of this compound (Fig. 2).

A significant increase in biomarkers of oxidative stress, including significant lipid peroxidation, increased GSSG levels, and depleted GSH content, was evident in brain mitochondria isolated from the hyperammonemic mice (Fig. 3). NAC administration (100, 200, and 400 mg/kg, i.p.) significantly mitigated biomarkers of oxidative stress in the brain mitochondria.
NAC and brain mitochondrial function in hyperammonemia

Effects of NAC on brain mitochondria biomarkers of oxidative stress was also not dose-dependent. However, the maximum antioxidative stress effects of NAC in brain mitochondria was found at a dose of 400 mg/kg (Fig. 3).

**Discussion**

Hepatic encephalopathy (HE) is a serious clinical complication. The ammonium ion (NH₄⁺) is the most suspected toxic molecule, which plays a pivotal role in the pathogenesis of HE [51-53]. NH₄⁺ is a neurotoxic agent [51-53]. Liver failure with different etiologies leads to disturbed urea cycle and hyperammonemia [51-53]. Acute or chronic liver injury associated with xenobiotics, infectious diseases, or cholestasis/cirrhosis could induce hyperammonemia and HE [2, 54-56]. HE needs urgent and specialist treatment to prevent permanent brain injury, coma, or patients’ death.

Several interconnected mechanisms have been identified for NH₄⁺ neurotoxicity [3, 11, 57-62]. Severe inflammation, N-methyl-D-aspartate (NMDA) receptor hyperactivation and excitotoxic response, oxidative/nitrosative stress, and mitochondrial impairment are proposed mechanisms of NH₄⁺-induced brain injury during hyperammonemia [3, 11, 57-64]. Previously, 

---

**Fig. 3.** Biomarkers of oxidative stress in brain mitochondria of acetaminophen (APAP; 800 mg/kg, i.p.)-treated mice. Data are given as mean ± SD (n = 8). Asterisks indicate significantly different as compared with the APAP group (*p < 0.05, ***p < 0.001). ns – not significant
Clinical and Experimental Hepatology 2/2020

we found that NAC administration to hyperammonemic animals significantly decreased brain tissue biomarkers of oxidative stress and improved animal locomotor activity [31]. In the current study, the effects of NAC on brain mitochondria as a crucial target of ammonia neurotoxicity were investigated.

Mitochondrial impairment and its consequent cellular energy crisis have been identified as a crucial mechanism for NH$_4^+$ neurotoxicity [3, 7, 10, 11, 57, 59, 62]. NH$_4^+$ could accumulate in the astrocytes and mitochondrial matrix through specific transporters [57, 65-67]. Afterward, NH$_4^+$ is metabolized to potentially mitotoxic metabolites such as glutamine [57]. NH$_4^+$ itself is also identified as a mitochondrial toxin [3, 57]. NH$_4^+$ or glutamine could induce mitochondrial impairment and decrease cellular energy metabolism through different mechanisms [3, 57]. It has been documented that NH$_4^+$ and glutamine are inducers of mitochondrial membrane permeability transition (mPT) [3, 57]. Induction of mPT is connected with dissipated mitochondrial membrane potential (ΔΨ), impairment of oxidative phosphorylation, and finally defective ATP production [3, 57]. MPT opening could also lead to the release of cell death mediators from this organelle [3, 57]. In the current study, significant mitochondrial permeabilization was detected in brain mitochondria isolated from hyperammonemic animals (Fig. 2).

The activity of mitochondrial electron transport complexes could be affected by NH$_4^+$ [3, 57]. On the other hand, different tricarboxylic acid cycle (TCA) enzymes, including α-ketoglutarate dehydrogenase (α-KGDH), isocitrate dehydrogenase, and malate dehydrogenase, could also be inhibited by NH$_4^+$ [3, 16, 68-70]. It has also been reported that NH$_4^+$ could significantly decrease pyruvate dehydrogenase activity [3, 14]. The inhibition of pyruvate dehydrogenase and TCA cycle enzymes will significantly decrease mitochondrial content of reducing equivalents such as nicotinamide adenine dinucleotide (NADH). NADH is essentially required for the activity of mitochondrial respiratory chain complexes. A significant decrease in the expression and activity of the mitochondrial electron transport chain (ETC) has also been documented in animal models of hyperammonemia [16, 71-75]. Inhibition of ETC by ammonia could significantly decrease energy metabolism in brain mitochondria (Fig. 2). On the other hand, NAC treatment significantly decreased biomarkers of oxidative stress in the brain mitochondria isolated from the APAP-treated animals [60]. Oxidative stress and mitochondrial impairment are two closely related events [78]. Cellular mitochondria are the primary sources of ROS [78]. Any defect in mitochondrial function could enhance mitochondria-facilitated ROS formation and cause severe oxidative stress [78]. Hence, mitochondrial-facilitated ROS formation could play a pivotal role in brain oxidative stress during hyperammonemia (Fig. 4) [3]. In the current study, we found that biomarkers of oxidative stress were significantly increased in the brain mitochondria isolated from hyperammonemic animals (Fig. 3). Interestingly, it has been documented that the synthesis of vital molecules such as GSH is decreased in different tissues, including the brain, during HE [79, 80]. Hence, interruption in the cytoplasmic level of GSH is a reason for lower mitochondrial GSH content (Fig. 3).

On the other hand, NAC treatment also significantly decreased biomarkers of oxidative stress in the brain mitochondria isolated from the APAP-treated animals (Fig. 3). Hence, mitigation of mitochondria-mediated oxidative stress could serve as one of the pivotal mechanisms by which NAC exerts its antioxidative effect in the brain tissue during HE (Fig. 4). Indeed, many other mechanisms could also be involved in the pathogenesis of ammonia neurotoxicity [81-83]. Several studies have mentioned the role of autophagy and apoptosis in ammonia-induced astrocytes or neuron injury in different experimental models [81-83]. Evaluating the effects of therapeutic agents such as NAC on these processes might give a better insight for the clinical use of these compounds as neuroprotective agents in HE.

Collectively, our data suggest that NAC administration not only improves brain oxidative stress bio-
markers and locomotor activity in hyperammonemic mice but also significantly prevents energy metabolism disturbances in the brain. Further investigations are warranted to reveal the clinical significance of these data in patients with HE.

Acknowledgments

The authors thank the Pharmaceutical Sciences Research Center and the Vice-Chancellor of Research Affairs of Shiraz University of Medical Sciences for providing technical and financial support of the current investigation (Grants: 19528/15283/15282/12133/14822).

Disclosure

The authors report no conflict of interest.

References

1. Felipo V. Hepatic encephalopathy: Effects of liver failure on brain function. Nat Rev Neurosci 2013; 14: 851-858.
2. Butterworth RF. Pathophysiology of hepatic encephalopathy: A new look at ammonia. Metab Brain Dis 2002; 17: 221-227.
3. Heidari R. Brain mitochondria as potential therapeutic targets for managing hepatic encephalopathy. Life Sci 2019; 218: 65-80.
4. Felipo V, Butterworth RF. Neurobiology of ammonia. Prog Neurobiol 2002; 67: 259-279.
5. Bémeur C, Butterworth RF. Liver-brain proinflammatory signalling in acute liver failure: Role in the pathogenesis of hepatic encephalopathy and brain edema. Metab Brain Dis 2013; 28: 145-150.
6. Bémeur C, Desjardins P, Butterworth RF. Evidence for oxidative/nitrosative stress in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2010; 25: 3-9.
7. Norenberg MD, Rao KVR, Jayakumar AR. Ammonia neurotoxicity and the mitochondrial permeability transition. J Bioenerg Biomembr 2004; 36: 303-307.
8. Rao KVR, Jayakumar AR, Norenberg MD. Ammonia neurotoxicity: role of the mitochondrial permeability transition. Metab Brain Dis 2003; 18: 113-127.
9. Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammonia neurotoxicity. Hepatology 2006; 44: 788-794.
10. Norenberg MD, Rao KVR, Jayakumar AR. Mechanisms of ammonia-induced astrocyte swelling. Metab Brain Dis 2005; 20: 303-318.
11. Norenberg MD, Rao KVR, Jayakumar AR. Signaling factors in the mechanism of ammonia neurotoxicity. Metab Brain Dis 2008; 24: 103-117.
12. Rao KVR, Norenberg MD. Glutamine in the pathogenesis of hepatic encephalopathy: the Trojan horse hypothesis revisited. Neurochem Res 2014; 39: 593-598.
13. Katunuma N, Okada M, Nishi Y. Regulation of the urea cycle and TCA cycle by ammonia. Adv Enzyme Regul 1966; 4: 317-335.
14. Lai JCK, Cooper AJL. Neurotoxicity of ammonia and fatty acids: Differential inhibition of mitochondrial dehydrogenases by ammonia and fatty acyl coenzymes A derivatives. Neurochem Res 1991; 16: 795-803.
15. Hindfelt B, Plum P, Duffy TE. Effect of acute ammonia intoxication on cerebral metabolism in rats with portacaval shunts. J Clin Invest 1977; 59: 386-396.
16. Rama Rao KV, Norenberg MD. Brain energy metabolism and mitochondrial dysfunction in acute and chronic hepatic encephalopathy. Neurochem Int 2012; 60: 697-706.
17. Yoon E, Babar A, Choudhary M, et al. Acetaminophen-induced hepatotoxicity: a comprehensive update. J Clin Trans Hepatol 2016; 4: 131-142.
18. Elbini Dhouib I, Jallouli M, Annabi A, et al. A minireview on N-acetylcysteine: An old drug with new approaches. Life Sci 2016; 151: 359-363.
19. Heidari R, Babaei H, Eghbal MA. Amiodaraine-induced toxicity in isolated rat hepatocytes and the cytoprotective effects of taurine and/or N-acetyl cysteine. Res Pharm Sci 2014; 9: 97-105.
20. Heidari R, Babaei H, Eghbal MA. Cytoprotective effects of tau- 
rine against toxicity induced by ionizediazide and hydrazine in iso-
lated rat hepatocytes. Arch Hig Rada Toksikol 2013; 64: 15-24.
21. Bulucu F, Ocal R, Karadurmus N, et al. Effects of N-acetylcyste-
ine, deeroxamine and selenium on doxorubicin-induced hepato-
toxicity. Biol Trace Elem Res 2009; 132: 184-196.
22. Zwingermann C, Bilodeau M. Metabolic insights into the hepa-
rotective role of N-acetylcysteine in mouse liver. Hepatology 2006; 43: 454-463.
23. Bavarsad Shalirpour R, Harrigan MR, Alexandrov AV. N-acetyl-
cysteine (NAC) in neurological disorders: mechanisms of action and therapeutic opportunities. Brain Behav 2014; 4: 108-122.
24. Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechan-
isms of N-acetylcysteine actions. Cell Mol Life Sci 2003; 60: 6-20.
25. Samuni Y, Goldstein S, Dean OM, et al. The chemistry and bi-
ological activities of N-acetylcysteine. Biochim Biophys Acta 2013; 1830: 4117-4129.
26. Xiong Y, Peterson PL, Lee CP. Effect of N-acetylcysteine on mi-
tochondrial function following traumatic brain injury in rats. J Neurotrauma 1999; 16: 1067-1082.
27. Nazrooqi M, Shenol N, Ghazizadeh V, et al. Neuroprotection 
induced by N-acetylcysteine and selenium against traumatic 
brain injury-induced apoptosis and calcium entry in hippocam-
pus of rat. Cell Mol Neurobiol 2014; 34: 895-903.
28. Eakin K, Baratz-Goldstein R, Pick CG, et al. Efficacy of N-acetyl 
cysteine in traumatic brain injury. PLoS One 2014; 9: e90617.
29. Hart AM, Terenghi G, Kellher JO, et al. Sensori neuroprotec-
tion, mitochondrial preservation, and therapeutic potential of 
N-acetyl-cysteine after nerve injury. Neuroscience 2004; 125: 91-101.
30. Hoffer BJ, Pick CG, Hoffer ME, et al. Repositioning drugs for 
traumatic brain injury – N-acetyl cysteine and Phenserine. 
J Biomed Sci 2017; 24: 71.
31. Ommati MM, Jamshidzadeh A, Niknahad H, et al. N-acetyl-
cysteine treatment blunts liver failure-associated impairment of 
locomotor activity. PharmNutrition 2013; 213: 39-42.
32. Takemoto K, Hatano E, Iwaisako K, et al. Necrostatin-1 protects 
against reactive oxygen species (ROS)-induced hepatotoxicity in 
acetaminophen-induced acute liver failure. FEBS Open Bio 2014; 4: 777-787.
33. Chataueret N, Desjardins P, Zwingermann C, et al. Direct molecular 
and spectroscopic evidence for increased ammonia removal capacity of skeletal muscle in acute liver failure. J Hepatol 2006; 44: 1083-1088.
34. Iglesias-Gonzalez J, Sánchez-Iglesias S, Beiras-Iglesias A, et al. A simple method for isolating rat brain mitochondria with high metabolic activity; effects of EDTA and EGTA. J Neurosci Methods 2013; 213: 39-42.
35. Caro AA, Adlong LW, Crocker SJ, et al. Effect of garlic-derived 
organosulfur compounds on mitochondrial function and integ-
rety in isolated mouse liver mitochondria. Toxicol Lett 2012; 
214: 166-174.
36. Zhao P, Kalhorn TF, Slattery JT. Selective mitochondrial gluta-
thione depletion by ethanol enhances acetaminophen toxicity 
in rat liver. Hepatology 2002; 36: 326-335.
37. Hossein N, Akram J, Reza H, et al. The postulated hepatotoxic 
metabolite of methimazole causes mitochondrial dysfunction 
and energy metabolism disturbances in liver. Pharm Sci 2016; 
22: 217-226.
38. Heidari R, Niknahad H. The role and study of mitochondrial 
impairment and oxidative stress in cholestasis. In: Vinken M 
ed.). Experimental Cholestasis Research. Springer, New York, 
NY 2019; 117-132.
39. Niknahad H, Heidari R, Mohammadzadeh R, et al. Sulfasalazine 
induces mitochondrial dysfunction and renal injury. Ren Fail 2017; 39: 745-753.
40. Chen Y, Xing D, Wang W, et al. Development of an ion-pair 
HPLC method for investigation of energy charge changes in 
cerebral ischemia of mice and hypoxia of Neuro-2a cell line. 
Biomed Chromatogr 2007; 21: 628-634.
41. Mosmann T. Rapid colorimetric assay for cellular growth and 
survival: application to proliferation and cytotoxicity assays. 
J Immunol Methods 1983; 65: 55-63.
42. Niknahad H, Heidari R, Alzuhairi AM, Najibi A. Mitochondrial 
dysfunction as a mechanism for pioglitazone-induced injury to 
HepG2 cell line. Pharm Sci 2015; 20: 169-174.
43. Heidari R, Jamshidzadeh A, Ommati MM, et al. Ammonia-in-
duced mitochondrial impairment is intensified by manganese co-exposure: relevance to the management of subclinical hepat-
ic encephalopathy and cirrhosis-associated brain injury. Clin Exp Hepatol 2019; 5: 109-117.
44. Ommati MM, Jamshidzadeh A, Heidari R, et al. Carnosine and 
histidine supplementation blunt lead-induced reproductive 
toxicity through antioxidative and mitochondria-dependent 
mechanisms. Biol Trace Elem Res 2019; 187: 151-162.
45. Eftekhari A, Ahmadian E, Panahi-Azar V, et al. Hepatoprotect-
tive and free radical scavenging actions of quercetin nanoparti-
cles on aflatoxin B1-induced liver damage: in vitro/in vivo stud-
ies. Artif Cell Nanomed Biotechnol 2018; 46: 411-420.
46. Jamshidzadeh A, Heidari R, Basavali M, et al. Taurine treatment 
protects brain and liver mitochondrial function in a rat mod-
el of fulminant hepatic failure and hyperammonemia. Biomed Pharmacother 2017; 86: 514-520.
47. Ommati MM, Heidari R, Jamshidzadeh A, et al. Dual effects of 
sulfasalazine on rat sperm characteristics, spermatogenesis, and 
steroidogenesis in two experimental models. Toxicol Lett 2018; 
284: 46-55.
48. Caro AA, Cederbaum AI. Synergistic toxicity of iron and arachi-
donic acid in HepG2 cells overexpressing CYP2E1. Mol Pharmacol 2001; 60: 742-752.
49. Meeks RG, Harrison S. Hepatotoxicology. CRC Press, New Y ork 
1991.
50. Truong DH, Eghbal MA, Hindmarsh W, et al. Molecular mech-
asms of hydrogen sulfide toxicity. Drug Metab Rev 2006; 38: 
733-744.
51. Felipo V. Advances in cirrhosis, hyperammonemia, and hepatic 
encephalopathy. Springer Science & Business Media 2012.
52. Braissant O, McLin VA, Cudalbu C. Ammonia toxicity to the 
brain. J Inherited Metab Dis 2013; 36: 595-612.
53. Dasarathy S, Mookerjee RP, Rackayova V, et al. Ammonia toxic-
ity: from head to toe? Metab Brain Dis 2017; 32: 529-538.
54. Friedman LS, Keefe EB. Handbook of liver disease. Elsevier 
Health Sciences, London 2011.
55. Tonyali O, Coskun U, Yildiz R, et al. Imatinib mesylate-induced 
acute liver failure in a patient with gastrointestinal stromal tu-
mors. Med Oncol 2010; 27: 768-773.
56. Tuhón MI, Alvarez M, Culebras JM, et al. An overview of ani-
mal models for investigating the pathogenesis and therapeutic 
strategies in acute hepatic failure. World J Gastroenterol 2009; 
15: 3086-3098.
57. Albrecht J, Norenberg MD. Glutamine: a Trojan horse in ammo-
nia neurotoxicity. Hepatology 2006; 44: 788-794.
NAC and brain mitochondrial function in hyperammonemia

58. Albrecht J, Jones EA. Hepatic encephalopathy: molecular mechanisms underlying the clinical syndrome. J Neurol Sci 1999; 170: 138-146.
59. Oja SS, Saranssaari P, Korpi ER. Neurotoxicity of ammonia. Neurochem Res 2017; 42: 713-720.
60. Norenberg MD, Jayakumar AR, Rama Rao KV. Oxidative stress in the pathogenesis of hepatic encephalopathy. Metab Brain Dis 2004; 19: 313-329.
61. Butterworth RF. Pathogenesis of hepatic encephalopathy and brain edema in acute liver failure. J Clin Exp Hepatol 2015; 5: 596-5103.
62. Rama Rao KV, Jayakumar AR, Norenberg MD. Role of oxidative stress in the ammonia-induced mitochondrial permeability transition in cultured astrocytes. Neurochem Int 2005; 47: 31-38.
63. Suárez I, Bodega G, Fernández B. Glutamine synthetase in brain: effect of ammonia. Neurochem Int 2002; 41: 123-142.
64. Norenberg MD, Rao KVR. The mitochondrial permeability transition in neurologic disease. Neurochem Int 2007; 50: 983-997.
65. Jayakumar AR, Norenberg MD. The Na-K-Cl Co-transporter in astrocyte swelling. Metab Brain Dis 2010; 25: 31-38.
66. Nagaraja TN, Brookes N. Intracellular acidification induced by passive and active transport of ammonium ions in astrocytes. Am J Physiol 1998; 274: C883-891.
67. Jayakumar AR, Liu M, Moriyama M, et al. Na-K-Cl cotransporter-1 in the mechanism of ammonia-induced astrocyte swelling. J Biol Chem 2008; 283: 33874-33882.
68. Hawkins RA, Mans AM. Cerebral function in hepatic encephalopathy. Hepatic Encephalopathy 1990; 272: 159-176.
69. Lavoie J, Giguère JF, Layrargues GP, et al. Activities of neuronal and astrocytic marker enzymes in autopsied brain tissue from patients with hepatic encephalopathy. Metab Brain Dis 1987; 2: 283-290.
70. Rao KVR, Norenberg MD. Cerebral energy metabolism in hepatic encephalopathy and hyperammonemia. Metab Brain Dis 2001; 16: 67-78.
71. Adlimoghaddam A, Sabbir MG, Albensi BC. Ammonia as a potential neurotoxic factor in Alzheimer’s disease. Front Mol Neurosci 2016; 9: 1-11.
72. Rama Rao KV, Mawal YR, Qureshi IA. Progressive decrease of cerebral cytochrome C oxidase activity in sparse-fur mice: role of acetyl-L-carnitine in restoring the ammonia-induced cerebral energy depletion. Neurosci Lett 1997; 224: 83-86.
73. Kosenko E, Felipo V, Montoliu C, et al. Effects of acute hyperammonemia in vivo on oxidative metabolism in nonsynaptic rat brain mitochondria. Metab Brain Dis 1997; 12: 69-82.
74. Rao KVR, Norenberg MD. Cerebral energy metabolism in hepatic encephalopathy and hyperammonemia. Metab Brain Dis 2001; 16: 67-78.
75. Veauvy CM, Wang Y, Walsh PJ, et al. Comparison of the effects of ammonia on brain mitochondrial function in rats and gulf toadfish. Am J Physiol 2002; 283: R598-R603.
76. da Silva MH, da Rosa EJF, de Carvalho NR, et al. Acute brain damage induced by acetaminophen in mice: effect of diphenyl diselenide on oxidative stress and mitochondrial dysfunction. Neurotox Res 2012; 21: 334-344.
77. Viswanathan G, Dan VM, Radhakrishnan N, et al. Protection of mouse brain from paracetamol-induced stress by Centella asiatica methanol extract. J Ethnopharmacol 2019; 236: 474-483.
78. Brookes PS, Yoon Y, Robotham JL, et al. Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol 2004; 287: C817-C833.
79. Ruszkiewicz J, Albrecht J. Changes of the thioredoxin system, glutathione peroxidase activity and total antioxidant capacity in rat brain cortex during acute liver failure: modulation by l-histidine. Neurochem Res 2015; 40: 293-300.
80. Ruszkiewicz J, Fręsko I, Hilgier W, Albrecht J. Decrease of glutathione content in the prefrontal cortical mitochondria of rats with acute hepatic encephalopathy: prevention by histidine. Metab Brain Dis 2013; 28: 11-14.
81. Soria LR, Brunetti-Pierri N. Ammonia and autophagy: An emerging relationship with implications for disorders with hyperammonemia. J Inherit Metab Dis 2019; 42: 1097-1104.
82. Lu K, Zimmermann M, Görg B, et al. Hepatic encephalopathy is linked to alterations of autophagic flux in astrocytes. EBioMedicine 2019; 48: 539-553.
83. Klejman A, Węgrzynowicz M, Szatmari EM, et al. Mechanisms of ammonia-induced cell death in rat cortical neurons: roles of NMDA receptors and glutathione. Neurochem Int 2005; 47: 51-57.